.
Topical; lowest
IV; lowest
Topical; highest
IV; highest
Compliance; once daily
Tolerance; twice daily
Efficacy; once daily
Efficacy; three times daily
Major age-related changes in the bladder include increased involuntary contractions
Urinary incontinence can be attributed to detrusor overactivity alone
Diminished detrusor contractile strength is a major age-related change
Urethral closure pressure decreases with age
Pelvic organ prolapse
Prior surgery
Prostate disease
A and B only
Decreased involuntary contractions
Increased voided volume
Decreased detrusor contractile strength
All of the above
Increased urethral closing pressure
The number but NOT density of striated fibers decreases
Prostate-induced mechanical urethral obstruction is common in females
None of the above
Differences in the incidence of ADEs
Formulation and manufacturer of the drug
Avoidance of ADEs to which the patient may be susceptible
Additional patient-based issues that may complicate the use of the drug
Oxybutynin
Solifenacin
Darifenacin
Fesoterodine
Incidences of ADE’s
Oxybutynin is always the primary choice
There is no difference between drug choices
Patient age
Dry mouth
Constipation
Alopecia
Altered cognition
Smaller voided volumes
Higher urine flow rate
Smaller bladder capacity
Increased post-voiding residual volume
Alterations in the mucosal and submucosal layers
Alterations in smooth muscle membranes
Decreased vascular density
Decreased blood flow
Alpha –Blockers and 5-ARI’s used in men with LUT symptoms from BPH are not very effective in reducing UI or urgency
Anticholinergic drugs are neither less efficacious nor significantly more likely to cause urinary retention
Desmopressin acetate is inappropriate for nocturia in older persons because of the risk of hyponatremic
Amitriptyline has robust evidence of efficacy and is supported by its anticholinergic effects
Detrol, Vesicare, Enablex, Toviaz
Sanctura, Vesicare, Toviaz, Enablex
Detrol, Enablex, Toviaz, Vesicare
Sanctura, Oxytrol, Enablex, Evista
Estrogen
Duloxetine
Amitriptyline
Oxybutynin
Increasing bladder capacity
Acting at the level of the sacral cord to facilitate sphincter contraction
Ablating detursor overactivity
Facilitate sphincter contraction through smooth muscle α-1A receptors
Tolterodine
Darifenacin
Oxybutynin
Fesoterodine
Solifenacin
Trospium
Oxybutynin
Fesoterodine
Correcting comorbid disease states
Correcting functional impairments
Optimizing medication therapy
All of the above
Elderly patients are at risk for developing adverse effects of UI medications
Etiology is usually a specific condition of the lower urinary tract
Concurrent medications should be considered for the cause of UI
UI is associated with an increase in fall risk
Detrusor overactivity
Diminished detrusor contractile strength
Increased number and density of striated and smooth muscle
Small bladder capacity
Increased vascular density and blood flow
Diminished detrusor contractile strength
Alterations in the mucosal and submucosal layers
"ultra-close abutments" in smooth muscle cells to facilitate
Gender
Age
Physical activity
Caffeine
Increased involuntary contractions
Detrusor overactivity
Decreased involuntary contractions
Diminished detrusor contractile strength
Elevated caveolae
“dense bands” in smooth muscle membranes
Tight spaces between muscle cells
None of the above
Trospium
Darifenacin
Oxybutinin
Solifenacin
Tolterodine
Oxybutynin
Darifenacin
Solifenacin
Oxybutynin
Tolterodine
Solifenacin
There is no difference in efficacy among UI therapies
Urge UI
Stress UI
Explosive UI
Bladder UI
NSAIDS
Estrogens
Statins
TCAs
Duloxetine
Oxybutynin
Tolterodine
Darifenacin
All antimuscarinics are metabolized by CYP-450 enzymes
During antimuscarinic therapy with older adults a major drug related ADE of concern is cognitive impairment
Currently there is insufficient evidence that one agent with in this class is "safer" for all older patients
Agents within this class prescribed for UI may be associated with drug-disease interactions ie advance diabetes, and parkison's disease
Decreased post-voiding residual volume
Increased post-voiding residual volume
Decreased nocturia
Increased detrusor contractile strength
“dense bands” in smooth muscle
Decreased axon sensitivity
Narrowing of spaces between muscle cells
Acetylcholine accumulation
Increased intra-abdominal pressure
Sphincter damage impairing closure
Detrusor overactivity
Impaired uretheral support
Detrusor overactivity
Impaired compensatory mechanisms
Bladder outlet obstruction
A and B only
An increase; impaired
A decrease; impaired
An increase; improved
A decrease; improved
Detrusor overactivity (DO)
Detrusor underactivity (DU)
Pyloric sphincter overactivity (PO)
None of the above
Alterations in the mucosal and sub-mucosal layers
Decreased vascular density and blood flow
Both A and B
None of the above
ADEs
Patient-based factors
Efficacy
Issues that may complicate use of a drug
Alterations in the mucosal and sub-mucosal layers
Increased vascular density
Decreased blood flow
A and C only
Detrusor overactivity (DO)
Diminished detrusor contractile strength
Obstruction due to the prostate
A and B
Increased involuntary contractions
Diminished destructor contractile strength
Destructor overactivity
Bladder changes only identified in women
Oxybutynin
Tolterodine
Solifenacin
Darifenacin
Oxybutynin
Tolterodine
Darifenacin
None of the above
50% reduction in leakage over a period of 3 months
No leakage recorded in a 3-5 day bladder diary
No leakage recorded in a 3 month bladder diary
50% reduction in leakage over a period of 1 month
Solifenacin
Darifenacin
Oxybutinin
None of the above
Ditropan
Detrol
Diprivan
A and B
Oral syrup
Gelnique 400mg/gm
Oral tablet
Transdermal jelly 100mg/gm
Hypokalemia
Hypocalcemia
Hyponatremia
Hypoalbuminemia
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.
Wait!
Here's an interesting quiz for you.